Clinical Trial Update: A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer after failure of docetaxel-based chemotherapy ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostate Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2019-07-18